Join
Live feed
·
PRReleasevia Quantisnow
Supernus Pharmaceuticals Inc. logo

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
SUPN· Supernus Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SUPN (Supernus Pharmaceuticals Inc.) and more on Quantisnow.